# Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

> **NCT04598269** · PHASE2 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 50 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** ATI-1777
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT04598269
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-30
- **Primary completion:** 2021-04-08
- **Final completion:** 2021-04-22
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04598269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04598269, "Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04598269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*